Corporate ActionJun 12, 2026, 09:31 AM
Virax Biolabs Shareholders Approve Share Consolidation
AI Summary
Virax Biolabs Group Ltd held its Extraordinary General Meeting of Shareholders, which was initially adjourned due to a lack of quorum. The meeting was reconvened on June 12, 2026, where shareholders approved two key proposals. These included a share consolidation on a basis of one (1) share for every ten (10) to thirty (30) outstanding ordinary shares, and the adoption of an amended and restated memorandum and articles of association to reflect the revised authorized share capital.
Key Highlights
- Shareholders approved a share consolidation of 1 ordinary share for every 10 to 30 outstanding ordinary shares.
- The share consolidation proposal received 517,694 votes For, 202,763 Against, and 5,951 Abstain.
- Shareholders approved the fourth amended and restated memorandum and articles of association.
- The articles of association amendment received 513,758 votes For, 175,512 Against, and 37,138 Abstain.
- The Extraordinary General Meeting was initially adjourned due to lack of quorum (3.6% attendance).
- The reconvened meeting proceeded with shareholders present constituting a quorum (3.65% attendance).
Price Impact
More from VRAX